

THRU ONLINE FILING

June 15, 2017

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,


**Sub: US FDA Update on Company's Active Pharmaceutical Ingredients (APIs)
manufacturing facility situated at Ratlam (Madhya Pradesh)**

Further to our letters dated July 24, 2014 and January 23, 2015, we now wish to inform you that the Company has received a communication from USFDA stating that all the drugs manufactured at the said manufacturing facility will be henceforth refused admission into United States (except API Chloroquine Phosphate, which exception will be reconsidered if shortage and/or medical necessity implications change) until the Company can demonstrate that the drugs manufactured at this manufacturing site and intended for the US market are in compliance with cGMP.

Kindly make note of the same.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.
www.ipca.com